Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-22-000063
Filing Date
2022-05-18
Accepted
2022-05-17 20:11:32
Documents
7
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 6-K a2022informationcircularfo.htm 6-K 20632
2 EX-99.1 finalonccircular2022.htm EX-99.1 501591
3 EX-99.2 oncolytics-proxydraft.htm EX-99.2 10713
4 image_2a.jpg GRAPHIC 74787
5 oncolytics-proxydraft001.jpg GRAPHIC 173479
6 oncolytics-proxydraft002.jpg GRAPHIC 217049
7 performance_graphx2022a.jpg GRAPHIC 166318
  Complete submission text file 0001129928-22-000063.txt   1404029
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 22936671
SIC: 2834 Pharmaceutical Preparations